Objective: Selective Estrogen Receptor Modulators (SERMs) reduce breast cancer risk by 38%.
Introduction
Breast cancer is the most frequently diagnosed cancer among women worldwide, with an estimated 1.38 million cases diagnosed in 2008, which accounted for approximately 23% of all new cancer cases (1) . A woman's individual risk of developing breast cancer is dependent on specific factors, the most important of which are increasing age and family history (2) . The average lifetime risk for an individual with two affected first-degree relatives is approximately 20%, compared to 13% for those with one affected firstdegree relative (3) . Women who carry a germline mutation in the BRCA1 or BRCA2 breast cancer predisposition genes have even higher risks (average lifetime risk estimates of 65% and 45% respectively (4)), though these account for a small proportion of breast cancers.
Risk management strategies for women with an elevated risk of breast cancer include riskreducing surgeries, namely risk-reducing mastectomy, risk-reducing pre-menopausal salpingooophorectomy and risk-reducing medication using selective estrogen receptor modulators (SERMs) (5) or aromatase inhibitors (6) . There is strong evidence that SERMs, such as tamoxifen and raloxifene, taken daily for five years reduce breast cancer risk by 38% (5) . However, current uptake of these agents is very low, even in women at high familial-risk (7) (8) (9) (10) (11) . Whilst it has been estimated that 15% of women in the United States between the ages of 35 and 79 could potentially benefit from tamoxifen (12) , less than 0.2% of women in this age range are taking tamoxifen for the prevention of breast cancer (13) . Similarly, a recent national cohort study in Australia (kConFab) revealed that fewer than 3% have used SERMs for prevention, and only 0.3% have done so while not enrolled in a clinical trial (12) .
Little is understood about the reasons for this less than anticipated uptake of SERMs. A c c e p t e d M a n u s c r i p t 5 our knowledge no study to date has utilized PMT, or any other theoretical models, to increase understanding of decision-making about SERMs.
Negative attitudes towards, and inadequate explanation of
The amount of protection motivation elicited is a function of the threat and coping appraisal processes. Essential to PMT is the postulation that the incentive to protect oneself from danger is a positive linear function of severity, vulnerability, response efficacy and self-efficacy and a negative linear function of rewards and response costs (20).
The present study aimed to test whether PMT factors are associated with intention to take SERMs in women who have a moderate to high risk of breast cancer (see Figure 1) . Consistent with Roger's (20) postulation of PMT, it was predicted that low rewards, high perceived vulnerability, high severity, high response efficacy, high self-efficacy and low response costs would be associated with intention to take SERMs. Further, in accordance with previous meta-analyses (26, 27) of PMT assessing health-related intentions, it was predicted that coping appraisal would be more strongly associated with intention than threat appraisal.
Methods

Participants
Participants were recruited from two Familial Cancer Clinics in Australia. Eligibility criteria included that participants be: considered by their Familial Cancer Centre clinician to be at moderate or high risk of breast cancer, competent in English, between the ages of 18 and 70 and unaffected with breast or ovarian cancer. Women who had undergone bilateral mastectomy or tested negative for a documented BRCA1 or BRCA2 family mutation were excluded. Participants who had previously undergone a risk-reducing oophorectomy were not excluded, as their remaining risk still made SERMs a viable option. Clinician estimates of risk were based on family history and BRCA1 and BRCA2 mutation status, using the definition formulated by The Australian National Breast and Ovarian Cancer Centre: high risk is greater than three times the population risk and moderate risk is one and a half to three times population risk (28).
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Procedure
Consecutive potentially eligible women were identified by each participating clinic from breast cancer risk assessment and high risk clinics. Clinicians sent women a letter advising them about the study with a 'permission to contact' form and a stamped, addressed return envelope. Women who gave permission were phoned by a researcher. Consenting women completed a web-based consent form and questionnaire. Those who preferred not to complete the questionnaire online, were mailed a paper-based questionnaire and consent form, with a stamped and addressed return envelope enclosed.
Materials
A fact sheet that provided information on SERMs, risk-reducing mastectomy and risk-reducing salpingo oophorectomy was provided to ensure all participants had at least a basic level of knowledge about risk-reducing options.
Measures
Demographic characteristics.
Variables assessed included: age, ethnicity, relationship status, menopausal status, BRCA1 or BRCA2 mutation status, and whether and how much the participant currently smoked cigarettes. Also included were: parity; if the woman had children whether they were daughters; plans to have children in the future; a history of thrombosis; a family and/or personal history of uptake of risk-reducing mastectomy and/or oophorectomy and/or SERMs.
Protection Outcome
The primary Protection Motivation outcome was assessed by a single item measuring intention to undergo SERMs treatment on a 5-point Likert-type scale anchored by very unlikely (1) to very likely (5) . All scales except vulnerability were responded to on 5-point Likert scales anchored by the labels: strongly disagree (1) and strongly agree (5). Composite subscale scores for threat and coping appraisal were generated as the sum of item scores, with higher scores indicating higher levels of the corresponding construct.
Data Analysis
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A c c e p t e d M a n u s c r i p t 8 All analyses were conducted using the Statistical Package for the Social Sciences (SPSS) version 17. Multiple linear regression analysis was used to assess predictors of intention to take SERMs. Potential covariates were assessed by computing Pearson correlations with intention to take SERMs. Variables were included in regression models if they were significantly correlated at the 0.25 level and/or had strong theoretical rationale, that is, were considered to have a meaningful relationship with the dependent variable in accordance with the recommendations of Hosmer and Lemeshow (34) . The control variables, age, risk status, having children, intention to have a mastectomy and intention to have an oophorectomy, were entered in model 1. All PMT variables were then entered into model 2.
To test the hypothesis whether coping appraisal would be more strongly associated with intention than threat appraisal, multiple linear regression was again used. Scores for severity, response-efficacy and self-efficacy variables were each standardized to scales ranging from zero to one hundred in line with the VAS measuring vulnerability, in order to increase comparability. Threat-appraisal was then computed by summing the severity and vulnerability scores, while coping-appraisal was generated by summing responseefficacy and self-efficacy scores for each participant. Both threat appraisal and coping appraisal were mean-centered. After entering covariates into model 1 of the regression analysis, threat appraisal and coping appraisal were entered into model 2 and 3 respectively in order to compare whether threat or coping appraisal accounted for more variance in intention to take SERMs.
Results
Sample
Of the 407 invitations mailed out, two were returned to sender and 117 women gave consent to complete this study. Of these, two women did not fit the eligibility criteria and were not invited to complete the questionnaire. One hundred and seven women completed the questionnaire and are included in the present analysis, representing a response rate of 26%. Analysis of de-identified data on nonresponders indicated that 53% of invited women at moderate risk participated in this study compared to 33% and 24% of invited women at high risk and women with a BRCA1 or BRCA2 mutation respectively.
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Pearson chi-square analysis revealed significant differences between the response rates of women at moderate risk and women with a BRCA1 or BRCA2 mutation χ 2 (1, N =376) = 8.14, p = .01.
The demographic and clinical characteristics of participants are summarized in Table 1 . The mean age for all participants was 43 (SD=10.8). The final sample included those who were BRCA1 or BRCA2 mutation positive (n=41), at high risk due to their family history but without a documented mutation (n=56) and at moderate risk due to their family history (n=10). Seventeen percent of women reported previously taking SERMs and 38% of women had a family member who has previously used SERMs, although the latter likely predominantly took SERMs after a diagnosis of breast cancer.
Intention to take SERMs
Forty-five percent of women indicated they would be likely or very likely to take SERMs in the future. Correlation analysis was conducted to assess relationships between the dependent variable and potential covariates (see Table 2 ). Although age did not demonstrate a significant correlation with intention, an a priori decision was made to include both age and risk status as covariates in all multiple linear regressions due to strong theoretical rationale (35, 36) . Intention to have a mastectomy and intention to have (or having had) an oophorectomy were included as binary covariates in all regressions, as research suggests women do not consider SERMs in isolation but rather as an addition or alternative to other such measures of risk reduction (37) .
History of blood clots and whether or not one smoked were investigated through correlation analysis with the dependent variable, however, no significant relationships were found and thus were not included as covariates.
A multiple linear regression was conducted to assess the predictors of intention to take SERMs.
Analysis indicated that the overall regression was significant, p<.001, and accounted for 52.2% of the total variance in intention (Table 3) . Model 1 accounted for a significant proportion of the variance (R 2 =.12, p M a n u s c r i p t 10 =.04). Model 2 accounted for an additional 40% of the variance, p<.001 ( A second multiple linear regression was conducted to assess the effects of threat appraisal and coping appraisal on intention. Analysis indicated the overall regression model accounted for 44% of the total variance in intention (see Table 4 ). Sensitivity-analysis excluding women who had previously taken SERMs was conducted for all analyses and revealed very similar results.
Discussion and Conclusion
Discussion
The present study was the first to our knowledge to apply any psychological theory in order to elucidate how women at increased risk of breast cancer make decisions regarding medical prevention using SERMs. Forty-five percent of women in the present study reported that they would be likely or very likely to take SERMs in the future. Whilst this is substantially greater than the reported uptake of chemoprevention, previous studies assessing intentions to take SERMs have ranged from 23% (38) to 62% (39) . The intention-behavior 'gap', which has been well-documented in the health literature, may account for the discrepancy between studies assessing intentions and actual uptake of SERMs (40). It was not feasible, however, to assess future behavior in the current analysis.
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PMT was found to be a useful theoretical framework for understanding women's intentions to take SERMs, with components of PMT explaining 40% of the variance in intention over and above the controlled-for variables. This amount of variance explained is comparable to that reported for breast cancer screening (39%)(22) but considerably greater than that reported for intention to perform breast selfexamination, where it explained only 25% (41) and 20% (42) of the variance.
In accordance with prediction, high levels of severity, vulnerability and response-efficacy were all associated with greater intention to take SERMs. Thus if women believe that breast cancer has severe consequences, that they are at high risk of developing breast cancer and that SERMs are effective in reducing risk, they are more likely to intend to take up SERMs. Perceived risk has previously been found to be predictive of both considering taking tamoxifen (38) and uptake of tamoxifen (32) . Notably, it is a welldocumented phenomenon that women overestimate their risk of breast cancer (35, 39, (43) (44) (45) and that perception of risk is rarely a direct comprehension of accurately understood probability information (32, 46) . Thus in medical consultations, particularly of women at moderate risk, health professionals need to carefully assess and discuss subjective risk.
In accordance with our hypothesis, and congruent with meta-analyses of PMT (26, 27), copingappraisal appeared to be a stronger predictor of intention than threat-appraisal. Thus, the present study adds further support to the growing body of evidence suggesting that self-efficacy and response-efficacy should be included in social-cognition models of health (25 A c c e p t e d M a n u s c r i p t
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Our results are partially consistent with meta-analytic findings of studies using PMT to predict cancer-related preventive behavior, where vulnerability and response efficacy consistently emerge as key predictors (26, 47) . Notably, while self-efficacy has emerged in the literature as the strongest predictor of intention (26, 27) it was not predictive of intention to take SERMs in the present study. One possible explanation for this inconsistency may be due to the nature of the protective behavior in this study. That is, few people would believe that they did not have the confidence to take a tablet a day.
PMT would predict that intention is a negative linear function of the response costs associated with taking SERMs (such as side effects) and reinforcements or rewards associated with not taking SERMs (such as relief from constant reminders of cancer risk). However, surprisingly neither rewards nor responsecosts accounted for a significant amount of variance in intention to take SERMs. This suggests, that either women do not put great weight on the side effects of SERMs or the opportunity to avoid cancer reminders in deciding whether or not to take SERMs, or that the measures used in the current study did not adequately assess these dimensions. The present study is only the third study predicting intention to undertake a health behavior (after Abraham et al. (48) and Helmes (49)) to include the rewards component. More research is needed to evaluate the complete PMT model. Until then, it is premature to conclude that side effects and the rewards associated with not taking SERMs, do not affect women's decision-making.
The present study has sampling and methodological limitations that warrant consideration. Previous research has demonstrated that women attending familial cancer clinics have above-average educational and socioeconomic levels suggesting that these women may not be representative of the broader population of women at increased risk of developing hereditary breast cancer (50-53). Nonetheless, our findings are highly relevant to countries such as Australia, where most assessment, genetic-testing and risk management of women at increased familial risk is done through Family Cancer Centers (10).
Further, our participants reported a higher prevalence of previous use of SERMs than would be expected from the previous literature. This may have been because we excluded women who had opted for surgical procedures, or because we recruited from clinics with positive attitudes to SERMs, or because SERMs users were more likely to be interested in the study. Women who take SERMs may be highly A c c e p t e d M a n u s c r i p t 13 motivated and proactive about reducing their risk of breast cancer, and may not be representative of women at high risk of breast cancer in the general population. However, in sensitivity analyses excluding the women who had already taken SERMs, the results looked very similar, suggesting that at least for the measured variables, previous SERMs use did not change the pattern of women's thinking about the decision to take SERMs.
We were only able to recruit ten women at moderate risk of breast cancer, partially as a function of our method of recruitment, which was primarily through high risk clinics. Furthermore, women at moderate risk may have been reassured by the risk assessment provided at the clinic and may have therefore been less motivated to participate in the study. In addition, the present study had a relatively low response rate of 26%.
We included women who had had a risk-reducing oophorectomy, because such women can benefit from, and are offered SERMs in the clinic; however women who have chosen to have a prophylactic oophorectomy may differ from other high risk women. We did not have enough such women in the sample to explore systematic differences in this group.
Another limitation of this study is that women are unlikely to consider SERMs in isolation but rather as an addition or alternative to other methods of risk reduction such as risk-reducing-mastectomy and risk-reducing-oophorectomy. However, it was not feasible in the current study to examine women's preferences for multiple methods of risk reduction.
Finally, due to the cross-sectional design of the present study, it is not known whether intention to take SERMs would necessarily translate into actual behavior. Future prospective cohort-studies are recommended.
Despite these limitations, the present study has a number of strengths. The sample consisted of women from familial cancer centers who were all at increased risk of breast cancer and candidates for risk prevention using SERMs. These women were recruited from two centers, in different states. Further, the sample included women from the three risk groups (moderate, high and mutation positive) in order to M a n u s c r i p t 14 represent women from all risk groups eligible to take SERMs. Moreover, objective risk status was obtained from clinicians and included as a covariate in all analyses to assess the potential differences between these groups.
Conclusion
Protection motivation theory provided a useful framework with which to explore factors associated with women's intentions to take SERMs. The degree to which a woman feels at risk of breast cancer, her perceptions of the seriousness of breast cancer and very importantly, her belief in the efficacy of SERMs, all contribute to her intention to take SERMs. Thus these issues require detailed discussion in the context of decision-making about risk reduction.
Practice Implications
The present findings have a number of implications for future research and clinical practice. Firstly, the results demonstrate that many women at increased risk of breast cancer are interested in using SERMs to reduce their risk.
The results suggest that to increase uptake of SERMs, health professionals should first focus on ensuring that women have accurate subjective risk perception and are informed about the proven long-term benefits of SERMs. It is important that clinicians not only provide women with information about the effectiveness of SERMs but also highlight the high quality of the studies from which this evidence was
obtained. An effective way for this information to be conveyed would be through genetic counseling or evidence-based decision-aids. As individual preferences and issues vary, a tailored approach to chemoprevention counseling may be of particular benefit. A c c e p t e d M a n u s c r i p t 3 
